Abstract
Increased breast cancer growth has been associated with increased expression of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases (RTKs). Upon activation, RTKs may transmit their oncogenic signals by binding to the growth factor receptor bound protein-2 (Grb2), which in turn binds to SOS and activates the Ras/Raf/MEK/mitogen-activated protein (MAP) kinase pathway. Grb2 is important for the transformation of fibroblasts by EGFR and ErbB2; however, whether Grb2 is also important for the proliferation of breast cancer cells expressing these RTKs is unclear. We have used liposomes to deliver nuclease-resistant antisense oligodeoxynucleotides (oligos) specific for the GRB2 mRNA to breast cancer cells. Grb2 protein downregulation could inhibit breast cancer cell growth; the degree of growth inhibition was dependent upon the activation and/or endogenous levels of the RTKs. Grb2 inhibition led to MAP kinase inactivation in EGFR, but not in ErbB2, breast cancer cells, suggesting that different pathways might be used by EGFR and ErbB2 to regulate breast cancer growth.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T. . 1986 Science 232: 1644–1646.
Alimandi M, Romano A and Curia M. . 1995 Oncogene 10: 1813–1821.
Bargmann C, Hung M-C and Weinberg R. . 1986 Nature 319: 226–234.
Baselga J, Norton L, Masui H, Coplan K, Miller Jr. W and Mendelsohn J. . 1993 J. Natl. Can. Inst. 85: 1327–1333.
Batzer A, Rotin D, Urena J, Skolnik E and Schlessinger J. . 1994 Mol. Cell. Biol. 14: 5192–5201.
Bonfini L, Karlovich C, Dasgupta C and Banerjee U. . 1992 Science 255: 603–606.
Bowtell D, Fu P, Simon M and Senior P. . 1992 Proc. Natl. Acad. Sci. USA 89: 6511–6515.
Buday L and Downward J. . 1993a Cell 73: 611–620.
Buday L and Downward J. . 1993b Mol. Cell. Biol. 13: 1903–1910.
Cance W and Liu E. . 1995 Breast Cancer Res. Treat. 35: 105–114.
Chrysogelos S and Dickson R. . 1994 Breast Cancer Res. Treat. 29: 29–40.
Clark S, Stern M and Horvitz H. . 1992 Nature 356: 340–344.
Daly R, Binder M and Sutherland R. . 1994 Oncogene 9: 2723–2727.
Di Fiore P, Pierce J, Kraus M, Seqatto O, King C and Aaronson S. . 1987 Science 237: 178–182.
DiGiovanna M and Stern D. . 1995 Cancer Res. 55: 1946–1955.
Downward J, Parker P and Waterfield M. . 1984 Nature 311: 483–485.
Duesbery N, Webb C, Leppla S, Gordon V, Klimpel K, Copeland T, Ahn N, Oskarsson M, Fukasawa K, Paull K and Van de Woude G. . 1998 Science 280: 734–737.
Ennis B, Valverius E, Lippman M, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A and Mendelsohn J. . 1989 Mol. Endocrinol. 3: 1830–1838.
Filmus J, Pollak M, Cailleau R and Buick R. . 1985 Biochem. Biophys. Res. Comm. 128: 898–905.
Fitzpatrick S, LaChance M and Schultz G. . 1984 Cancer Res. 44: 3442–3447.
Gardner A, Vaillancourt R and Johnson G. . 1993 J. Biol. Chem. 268: 17896–17901.
Harris A, Nicholson S, Sainsbury J, Farndon J and Wright C. . 1989 J. Steroid Biochemistry 34: 123–131.
Hazan R, Margolis B, Dombalagian M, Ullrich A, Zilberstein A and Schlessinger J. . 1990 Cell Growth Diff. 1: 3–7.
Heldin C-H. . 1996 Cell Signalling, Vol. 27: Cancer Surveys. Parker, P. and Pawson, T. (eds). Cold Spring Harbor Laboratory Press: New York pp. 7–24.
Hu Q, Klippel A, Muslin AJ, Fantl W and Williams L. . 1995 Science 268: 100–102.
Hudziak R, Schlessinger J and Ullrich A. . 1987 Proc. Natl. Acad. Sci. USA 84: 7159–7163.
Janes P, Daly R, deFazio A and Sutherland R. . 1994 Oncogene 9: 3601–3608.
Jardines L, Weiss M, Fowble B and Greene M. . 1993 Pathobiol. 61: 268–282.
Kallioniemi O-P, Kallioniemi A, Kurisu W, Thor A, Chen L-C, Smith H, Waldman F, Pinkel D and Gray J. . 1992 Proc. Natl. Acad. Sci. USA 89: 5321–5325.
Koenders P, Beex L, Kienhuis C, Kloppenborg P and Benraad T. . 1992 Breast Cancer Res. Treat. 23: 134–145.
Li K, Shao R and Hung M-C. . 1998 Proc. Am. Assoc. Cancer Res. 39: 1404.
Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B and Schlessinger J. . 1993 Nature 363: 85–88.
Lowenstein E, Daly R, Batzer A, Li W, Margolis B, Lammers R, Ullrich A, Skolnik E, Bar-Sagi D and Schlessinger J. . 1992 Cell 70: 431–442.
Majeti R, Bilwes A, Noel J, Hunter T and Weiss A. . 1998 Science 279: 88–91.
Marais R and Marshall C. . 1996 Cell Signalling, Vol. 27: Cancer Surveys. Parker, P. and Pawson, T. (eds). Cold Spring Harbor Laboratory Press: New York pp. 101–125.
Margolis B, Lax R, Kris R, Dombalagian M, Honegger A, Howk R, Givol D, Ullrich A and Schlessinger J. . 1989 J. Biol. Chem. 264: 10667–10671.
Nicholson S, Halcrow P, Sainsbury J, Angus B, Chanbers P, Farndon J and Harris A. . 1988 Br. J. Cancer 58: 810–814.
Pawson T. . 1995 Nature 373: 573–580.
Peles E, Lamprecht R, Ben-Levy R, Tzahar E and Yarden Y. . 1992 J. Biol. Chem. 267: 12266–12274.
Pendergast A, Quilliam L, Cripe L, Bassing C, Dai Z, Li N, Batzer A, Rabun K, Der C, Schlessinger J and Gishizky M. . 1993 Cell 75: 175–185.
Pietras R, Arboleda J, Reese D, Wongvipat N, Pegram M, Ramos L, Gorman C, Parker M, Sliwkowski M and Slamon D. . 1995 Oncogene 10: 2345–2446.
Ram T and Ethier S. . 1996 Cell Growth Diff. 7: 551–561.
Roche S, Koegl M and Courtneidge S. . 1994 Proc. Nat. Acad. Sci. USA 91: 9185–9189.
Rodriguez-Viciana P, Warne P, Dhand R, Vanhaesebroeck B, Gout I, Fry M, Waterfield M and Downward J. . 1994 Nature 370: 527–532.
Rodriguez-Viciana P, Warne P, Vanhaesebroeck B, Waterfield M and Downward J. . 1996 EMBO J. 15: 2442–2451.
Rozakis-Adcock M, Fernley R, Wade J, Pawson T and Bowtell D. . 1993 Nature 363: 83–85.
Schlessinger J and Ullrich A. . 1992 Neuron 9: 383–391.
Segatto O, Pelicci G, Giuli S, Digiese G, DiFore P, McGlade J, Pawson T and Pelicci P. . 1993 Oncogene 8: 2105–2112.
Sepp-Lorenzino L, Eberhard I, Ma Z, Cho C, Serve H, Liu F, Rosen N and Lupu R. . 1996 Oncogene 128: 1679–1687.
Simon M, Bowtell D, Dodson G, Laverty T and Rubin G. . 1991 Cell 67: 701–716.
Simon M, Dodson G and Rubin G. . 1993 Cell 73: 169–177.
Skorski T, Kanakaraj P, Ku D-H, Nieborowska-Skorska M, Ratajczak M, Wen S-C, Zon G, Gewirtz A, Perussia B and Calabretta B. . 1995 Blood 86: 726–736.
Slamon D, Clark M, Wong S, Levin W, Ullrich A and McAuire W. . 1987 Science 235: 177–181.
Stern M, Marenger L, Daly R, Lowenstein E, Kokel M, Batzer A, Olivier P, Pawson T and Schlessinger J. . 1993 Mol. Biol. Cell. 4: 1175–1188.
Suen K, Bustelo X, Pawson T and Barbacid M. . 1993 Mol. Cell. Biol. 13: 5500–5512.
Tan M, Yao J and Yu D. . 1997 Cancer Res. 57: 1199–1205.
Tari A, Arlinghaus R and Lopez-Berestein G. . 1997 Biochem. Biophys. Res. Comm. 235: 383–388.
Treisman R. . 1996 Curr. Opin. Cell Biol. 8: 205–215.
Ullrich A and Schlessinger J. . 1990 Cell 61: 203–212.
Vanhaesebroeck B, Stein R and Waterfield M. . 1996 Cell signalling, Vol. 27: Cancer Surveys. Parker, P. and Pawson, T. (eds). Cold Spring Harbor Laboratory Press: New York pp. 249–270.
Velu T, Beguinot L, Vass W, Willingham M, Merlino G, Pastan I and Lowy D. . 1987 Science 238: 1408–1410.
Xie Y, Pendergast A and Hung M-C. . 1995 J. Biol. Chem. 270: 30717–30724.
Yablonski D, Kuhne M, Kadlecek T and Weiss A. . 1998 Science 281: 413–416.
Yu D, Liu B, Tan M, Junzhi L, Wang S-S and Hung M-C. . 1996 Oncogene 13: 1359–1365.
Zhang L, Chang C, Bacus S and Hung M-C. . 1995 Cancer Res. 55: 3890–3896.
Acknowledgements
This research was supported in part by the UT MD Anderson Cancer Center Breast Cancer Research Program (to AMT) and the Gabriella Rich Leukemia Foundation (to GLB). We are very grateful for Alka Mehta's technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tari, A., Hung, MC., Li, K. et al. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene 18, 1325–1332 (1999). https://doi.org/10.1038/sj.onc.1202422
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202422
Keywords
This article is cited by
-
Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists
Molecular Diversity (2023)
-
Spatial transcriptomics at subspot resolution with BayesSpace
Nature Biotechnology (2021)
-
Blood miRNomes and transcriptomes reveal novel longevity mechanisms in the long-lived bat, Myotis myotis
BMC Genomics (2016)
-
Transcription factor and microRNA-regulated network motifs for cancer and signal transduction networks
BMC Systems Biology (2015)
-
Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor γ
Cell Research (2009)